X T L Biopharmaceuticals reported $1.1M in Operating Expenses for its fiscal quarter ending in December of 2024.


Operating Expenses Change Date
Alaunos Therapeutics USD 759K 391K Dec/2024
Bioline Rx USD 2.61M 36K Jun/2025
Teva Pharmaceutical Industries USD 3.28B 95M Jun/2025
X T L Biopharmaceuticals USD 1.1M 175K Dec/2024